Traduction de «quarterly and the 12-month » (Néerlandais → Français) :

Novartis investor event: Oncology and pipeline update Fourth quarter and full-year 2009 results Annual General Meeting First quarter 2010 results Second quarter and first half 2010 results Third quarter and first nine months 2010 results
Dates importantes 9 décembre 2009 Journée des investisseurs Novartis: le point sur Oncologie et son pipeline 26 janvier 2010 Résultats du quatrième trimestre et de l’exercice 2009 26 février 2010 Assemblée générale annuelle 20 avril 2010 Résultats du premier trimestre 2010 15 juillet 2010 Résultats du deuxième trimestre et du premier semestre 2010 21 octobre 2010 Résultats du troisième trimestre et des neuf premiers mois de 2010

Annual General Meeting (Basel) First quarter 2009 results Second quarter and first half 2009 results Third quarter and first nine months 2009 results
Dates importantes 24 février 2009 Assemblée générale annuelle (Bâle) 23 avril 2009 Résultats du premier trimestre 2009 16 juillet 2009 Résultats du deuxième trimestre et du premier semestre 2009 22 octobre 2009 Résultats du troisième trimestre et des neuf premiers mois de 2009

These condensed consolidated financial statements for the three-month quarterly and the 12-month periods ended December 31, 2008, were prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” and accounting policies set out in the 2008 Annual Report published on January 28, 2009.
Les comptes consolidés simplifiés pour le trimestre et la période de douze mois se terminant le 31 décembre 2008 ont été établis conformément à la norme comptable internationale 34 concernant l’information financière intermédiaire (IAS 34 « Interim Financial Reporting ») et aux normes comptables décrites dans le rapport annuel 2008 publié le 28 janvier 2009.

Third quarter and first nine months 2009 results Novartis investor event: Oncology and pipeline update (Basel) Fourth quarter and full-year 2009 results
Dates importantes 22 octobre 2009 Résultats du troisième trimestre et des neuf premiers mois de 2009 9 décembre 2009 Journée des investisseurs Novartis, le point sur Oncologie et le pipeline (Bâle) Janvier 2010 Résultats du quatrième trimestre et de l’exercice 2009

Strong financial performance in the third quarter and for nine months
Forte performance financière au troisième trimestre et sur neuf mois

o Core EPS improves 16% (+19% cc) to USD 1.36; nine months core EPS up 23% (+22% cc); third quarter EPS up 6% (+12% cc) to USD 0.99; nine months EPS +24% (+22% cc)
tcc) sur neuf mois; hausse du BPA de 6% (+12%) à USD 0,99 au troisième trimestre et de +24% (+22% tcc) sur neuf mois

Nine months to September 30 and third quarter
Neuf mois au 30 septembre et troisième trimestre

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

The absolute probability of not smoking at 6 to 12 months was greater in trials which provided high-intensity additional support, rather than low-intensity, particularly with nicotine gum, although this was of no significance.
The absolute probability of not smoking at 6 to 12 months was greater in trials which provided high-intensity additional support, rather than lowintensity, particularly with nicotine gum, although this was of no significance.

Raloxifen for prevention of glucocorticoid-induced bone loss: a 12-month randomized doubleblinded placebo-controlled trial.
Raloxifen for prevention of glucocorticoid-induced bone loss: a 12-month randomized double-blinded placebo-controlled trial.